Venetoclax plus chemotherapy for acute leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies how well venetoclax combined with chemotherapy treats newly diagnosed or returning (relapsed) or hard-to-treat (refractory) acute myeloid leukemia (AML). It’s mainly for people who can’t use standard AML therapy well, or whose disease came back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of AML (or sometimes high-risk MDS with at least 10% abnormal cells/blasts).
- You’re 65 or older, or if younger you may still qualify depending on the study’s overall plan (the trial focuses on people considered able to handle intensive chemo).
- Your general health is good enough for treatment (ECOG 0–2).
- Your kidney and liver tests are within limits (kidney function creatinine clearance ≥ 30; bilirubin and AST/ALT not too high).
- For Part 1: your AML is relapsed, refractory, or you couldn’t tolerate standard AML treatment after at least one prior AML treatment.
- You can take oral medicines reliably (no swallowing problems or gut conditions that limit absorption).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of venetoclax with liposome chemotherapy (daunorubicin and cytarabine) for adults with acute myeloid leukemia (AML) that is back after treatment or not responding, and for some newly diagnosed cases. It aims to shrink leukemia and help more people achieve remission.
This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.
This trial studies venetoclax combined with CLAG-M chemotherapy to treat adults with high-risk acute myeloid leukemia (AML) or related high-grade blood cancers. It aims to improve control of the disease, especially in people whose AML is considered high risk.
This study tests whether adding venetoclax to a specific busulfan-based chemotherapy plan improves outcomes for people with high-risk AML or MDS. It mainly targets patients whose leukemia/marrow disease still has high-risk features or measurable disease after initial treatment.
This trial tests adding venetoclax to standard chemotherapy to help people with newly diagnosed acute myeloid leukemia (AML) or high-risk MDS (MDS-EB-2) live longer and reduce cancer activity. You may benefit if you’re eligible for intensive chemotherapy and meet specific blood, organ, and treatment timing requirements.
This early-phase study tests whether venetoclax combined with intensive chemotherapy can treat AML (acute leukemia) and certain advanced MDS. It’s for people who are newly diagnosed (or certain high-risk blood cancers) and can safely tolerate strong treatment.
Hear when a new High Risk Myelodysplastic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.